Bryan Garnier - GENSCRIPT BIOTECH CORP (1548) GENSIGHT BIOLOGICS (BUY, TP EUR16) | French ANSM approves LUMEVOQ cohort ATU:

Report

Bryan Garnier

Dylan Van Haaften

GENSIGHT BIOLOGICS (BUY, TP EUR16) | French ANSM approves LUMEVOQ cohort ATU:

GENSIGHT BIOLOGICS (BUY, TP EUR16) | French ANSM approves LUMEVOQ cohort ATU

05/07/2021 3 EN

Underlying

GENSCRIPT BIOTECH CORP

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Dylan Van Haaften

Other Reports on these Companies

Aequitas Research

Legend Biotech Follow-on Offering

Legend Biotech, a non-wholly owned subsidiary of Hong Kong-listed GenScript, is planning to raise up to US$250m in its follow-on offering. The company last raised cash in Dec 2021 in a similar sized deal, which ended up doing very well after a sharp share price correction. In this note, we will talk about the deal dynamics and run the deal through our ECM framework.

EUR 95.47

July 26, 2022 July 26, 2022 1 EN

Independent Investment Research

Monthly LMI Update Independent Investment Research

Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked. This compares to the total dividends of 5 cents per share in FY20. The Board has confirmed that, in...

August 6, 2021 August 6, 2021 10 EN

Cinclus: agreement with the FDA on the iPSP

Similar to the agreement for the PIP concluded with the EU's EMA a couple of weeks ago, Cinclus has reached an agreement with the FDA on the company’s initial Paediatric Study Plan (iPSP) for linaprazan glurate, which is a prerequisite for market approval for adult use in the US. The study plan wil

14h / 48m 14h / 48m 1 EN

Maria Vara

Maria Vara

BICO: divests Nanoscribe for EUR26m in line with BICO 2.0 Strategy

BICO has agreed to sell Nanoscribe to LAB14 GmbH for an equity value of EUR26m (SEK294m), with the transaction set to close in Q4 2024. We are pleased to see the company executing the BICO 2.0 strategy shared during CMD 2024, which designates Nanoscribe as non-core due to its primary focus outside

14h / 57m 14h / 57m 1 EN

Aurelien Deside

Aurelien Deside

Exclusive Networks: expanding into the US with Cloudrise acquisition

Yesterday evening, Exclusive Networks announced the acquisition of 100% of Cloudrise, a security services provider headquartered in the USA. This acquisition represents a positive step towards the continued penetration of the highly attractive US cybersecurity market, which the group sees as a key

14h / 59m 14h / 59m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

GENSIGHT BIOLOGICS (BUY, TP EUR16) | French ANSM approves LUMEVOQ cohort ATU:

Legend Biotech Follow-on Offering

Monthly LMI Update Independent Investment Research

Cinclus: agreement with the FDA on the iPSP

BICO: divests Nanoscribe for EUR26m in line with BICO 2.0 Strategy

Exclusive Networks: expanding into the US with Cloudrise acquisition

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe